Cancer immunotherapy .net
Information on human tumours
pilot studies 1
tumour type
Hepatocellular carcinoma
Data in brief:

4 out of 5 patients treated, with a life expectency of less than 3 - 6 months, survived over 2 years

Clinical phase II research continues
Krastev et al. 2005
tumour type
Interleukin-2 (IL-2)
Mechanism of IL-2 therapy of cancer

Cancers sensitive to IL-2
Surgery and IL-2
Radiotherapy and IL-2
Chemotherapy and IL-2

I want to co-operate (doctors)
Frequently Asked Questions (FAQs)
Information for doctors
Information for patients
I want to support this research or  more information on the EPTI fund supporting this research
Our research is supported by Stichting ter bevordering van het onderzoek in de Experimentele Pathologie en in het bijzonder in de TumourImmunologie. Stichting EPTI, IJselstein, The Netherlands